| 名稱 | FCGR2A/HEK293 |
| 型號(hào) | CBP74077 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | FCGR2A/HEK293，凍存條件：90% FBS+10% DMSO； |
產(chǎn)品搜索
相關(guān)文章
- 羅氏乳腺癌新藥獲英國(guó)NICE批準(zhǔn)用于HER2乳腺癌新輔助治療
- 耐藥ATCC細(xì)胞株如何構(gòu)建看完就會(huì)知道
- 熱門CTLA4&PD1/L1雙靶點(diǎn)抗體活性檢測(cè)細(xì)胞模型
- 增強(qiáng)腫瘤免疫療法新靶點(diǎn)：ADORA2B（腺苷A2B受體）
- 細(xì)胞株的STR鑒定技術(shù)分享
- 針對(duì)ctDNA的MRD檢測(cè)，你參與了嗎？
- 非小細(xì)胞肺癌免疫治療 先放療更有效
- 剛收到的細(xì)胞株如何進(jìn)行合理的處理？
- CD47/PD-(L)1 雙靶點(diǎn)細(xì)胞篩選模型簡(jiǎn)介
- 【靶點(diǎn)模型+診斷質(zhì)控】BTK C481S的藥物開發(fā)和診斷
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74077FCGR2A/HEK293
- 詳細(xì)內(nèi)容
| I. Background | |
| FCGR2A (FcγRIIa) is a Protein Coding gene. Diseases associated with FCGR2A include Cystic Fibrosis and Systemic Lupus Erythematosus. Among its related pathways are Innate Immune System and Microglia Activation During Neuroinflammation: Overview. | |
| II. Description | |
| Recombinant HEK293 cells constitutively expressing FCGR2A. | |
| III. Introduction | |
| Host Cell: | HEK293 |
| Expressed gene: | FCGR2A（FcγRIIa） |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | DMEM+10%FBS+100μg/ml Hygromycin B |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Binding Assay,FACS |
| IV. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Kidney |
| Morphology: | Epitheloid cell |
| Growth Properties: | Adherent |
| Ⅴ. Representative Data | |
Figure 1.Recombinant FCGR2A/HEK293 constitutively expressing FCGR2A(FcγRIIa). | |
會(huì)員_a.png)